| Name | Title | Contact Details |
|---|
ZEE MEDICAL SERVICE COMPANY is a Reading, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.) is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure ulcers (bedsores).
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic.
Bioventus®Inc. (Nasdaq: BVS) develops Innovations for Active Healing and its mission is to make a difference by helping patients resume and enjoy active lives. The Company has products for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Established in 2012, Bioventus is headquartered in Durham, NC. The company has more than 800 employees worldwide and its international headquarters is in Hoofddorp, The Netherlands. Bioventus also has offices in Memphis, TN, Valencia, CA, Hod Hasharon, Israel and Mississauga, Ontario, Canada. Bioventus works with patients, payers and health care providers throughout the world.
PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.